Characterizing the PK and PK-PD variability of infliximab in RA 6 to 12 weeks [clinicaltrials_resource:05beb05da9194d38328a95b116ffe0f4]
Rhumatoid arthritis patient currently receiving infliximab
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Characterizing the PK and PK-PD variability of infliximab in RA 6 to 12 weeks [clinicaltrials_resource:05beb05da9194d38328a95b116ffe0f4]
Rhumatoid arthritis patient currently receiving infliximab
Bio2RDF identifier
05beb05da9194d38328a95b116ffe0f4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:05beb05da9194d38328a95b116ffe0f4
measure [clinicaltrials_vocabulary:measure]
Characterizing the PK and PK-PD variability of infliximab in RA
time frame [clinicaltrials_vocabulary:time-frame]
6 to 12 weeks
description
Rhumatoid arthritis patient currently receiving infliximab
identifier
clinicaltrials_resource:05beb05da9194d38328a95b116ffe0f4
title
Characterizing the PK and PK-PD variability of infliximab in RA 6 to 12 weeks
@en
type
label
Characterizing the PK and PK-P ...... eb05da9194d38328a95b116ffe0f4]
@en